ClinicalTrials.gg
Status unknownNCT01444859Updated Oct 24, 2012

Trenev Trio®/Healthy Trinity® for Recurrent Gastrointestinal Symptoms

A Phase 2/3 interventional study of Trenev Trio®/Healthy Trinity® and Placebo in Recurrent Gastrointestinal Symptoms, sponsored by Sprim Advanced Life Sciences. Status unknown at 5 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-24.

Sponsored by Sprim Advanced Life Sciences · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2011), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 2/3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Clinical trial to compare safety and effectiveness of 10-week supplementation with Trenev Trio®/Healthy Trinity® vs. placebo in otherwise healthy subjects with recurrent gastrointestinal symptoms.

Read the detailed description

This study is a double-blind, randomized, placebo-controlled, parallel group trial comparing the safety and effectiveness of supplementation with Trenev Trio®/Healthy Trinity® vs. placebo in otherwise healthy subjects with recurrent gastrointestinal symptoms. Subjects will be recruited and, following successful completion of a 2-week run-in period, will be randomized to Trenev Trio®/Healthy Trinity® or placebo and will consume their assigned study product daily for 10 weeks. The study endpoints of this trial include relief of overall gastrointestinal symptoms, acid indigestion, abdominal cramping, constipation, diarrhea, gas, and bloating as well as product safety over the 10-week supplementation period.

02

Conditions studied

  • Recurrent Gastrointestinal Symptoms
03

In context

Lead sponsor

Sprim Advanced Life Sciences is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. between 18.5 through 39.9 kg/m2
  3. At least three symptoms rated between 4 to 6 in severity (moderate to severe discomfort) on a 1 to 7 scale, one of which must be acid indigestion as determined by the "Reflux Syndrome" score
  4. Self-reported "acid indigestion" symptoms (including pain/discomfort beneath the breastbone, bitter fluid in the mouth, or bloating/nausea after eating) at least 3 times per week over the previous 4 weeks
  5. Agree to use throughout study period, unless or surgically sterile (females only)
  6. Able to understand and voluntarily consent to the study and understand it's nature and purpose including potential risks, and side effects

Exclusion criteria

Exclusion Criteria:

  1. Any GSRS symptom rated a 7 in severity (very severe discomfort) on a 1 to 7 scale
  2. Diagnosed gastrointestinal disease/complication or functional bowel disorder (e.g. IBS, functional constipation, IBD, ulcer, etc.) based on physical examination or documented medical history that, in the investigator's opinion, may affect subject safety or confound the evaluation of the study endpoints
  3. Any non-gastrointestinal disease/complication that, in the investigator's opinion, may affect subject safety or confound the evaluation of the study endpoints
  4. Regular (>3 days per week) prescription medication use for any gastrointestinal disease/condition
  5. Recent (\<6 months) abdominal surgery for any reason
  6. Immunodeficiency
  7. Recent change in anti-psychotic medication within the previous 3 months
  8. Systemic use within the prior month, excluding regular use of asthma medication
  9. Pregnant female or breastfeeding
  10. Eating disorder
  11. Recent (within 2 weeks) antibiotic administration
  12. History of alcohol, drug, or medication abuse
  13. Daily consumption of probiotics, fermented milk, and/or yogurt
  14. Known allergies to any substance in the study product
  15. Participation in another study with any product within 30 days of screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Placebo comparator
    Placebo capsule

    40 subjects allocated to daily placebo capsule for 10 weeks

    Dietary Supplement: Placebo

  • Experimental
    Trenev Trio®/Healthy Trinity®

    80 subjects allocated to Trenev Trio®/Healthy Trinity® for 10 weeks

    Dietary Supplement: Trenev Trio®/Healthy Trinity®

Interventions

  • Dietary supplementTrenev Trio®/Healthy Trinity®

    Drug page: Probiotic

    Trenev Trio®/Healthy Trinity® (1 capsule, 2x/day for 10 weeks), which offers a daily dose of: a) Lactobacillus acidophilus NAS strain (10 billion CFU), b) Bifidobacterium bifidum Malyoth strain (40 billion CFU), and c) Lactobacillus delbrueckii subspecies bulgaricus LB-51 strain (10 billion CFU)

    Also known as: Probiotic, Active

  • Dietary supplementPlacebo

    Daily placebo for 10 weeks

    Also known as: Inactive, Control

06

What researchers measure

Primary outcomes

  1. Mean total Gastrointestinal Symptom Rating Scale (GSRS) score

    Time frame: 10 weeks

  2. Gastrointestinal Quality of Life Index (GIQLI) total score

    Time frame: 10 weeks

Secondary outcomes

  1. Gastrointestinal Symptom Rating Scale subscores

    Time frame: 10 weeks

  2. Gas severity

    Time frame: 10 weeks

  3. Bloating severity

    Time frame: 10 weeks

  4. Acid indigestion severity

    Time frame: 10 weeks

  5. Abdominal cramping severity

    Time frame: 10 weeks

  6. Stool consistency (measured with Bristol Stool Form Scale)

    Time frame: 10 weeks

  7. Stool frequency

    Time frame: 10 weeks

  8. Concomitant medication use

    Time frame: 10 weeks

  9. Adverse event frequency

    Time frame: 10 weeks

  10. Adverse event severity

    Time frame: 10 weeks

07

Study locations

5 sites
  • Axis Clinical Trials
    Los Angeles, California 90036, United States
  • Sprim ALS
    San Francisco, California 94109, United States
  • Research Across America
    West Lawn, Pennsylvania 19609, United States
  • Research Across America
    Carrollton, Texas 75010, United States
  • Clinical Research Associates of Tidewater
    Norfolk, Virginia 23507, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 24, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01444859
Lead sponsor
Sprim Advanced Life Sciences
Collaborators
The National Institute of Probiotics
Responsible party
Sponsor
First posted
Oct 3, 2011
Start date
Feb 2012
Primary completion
Aug 2012
Completion
Nov 2012 (estimated)
Last update
Oct 24, 2012

Study contacts

Duane Wombolt, MD
principal investigator · Clinical Research Associates of Tidewater
Jeffrey Stewart, MD
principal investigator · Research Across America
Michael Sinitsa, MD
principal investigator · Research Across America
Helen Stacey, MD
principal investigator · Diablo Clinical Research
Lydie Hazan, MD
principal investigator · Axis Clinical Trials
JoAnn Hattner, MPH, RD
principal investigator · Sprim ALS

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion